SDIX (NASDAQ: SDIX), a leading provider of In Vitro Diagnostic (IVD) reagents, today announced its plan to introduce a new polyclonal antisera to its product line for the IVD market. The product, Apo B, will be available as antisera and in fractionated forms. Antibodies to Apo B will be launched on July 26, 2011, at the annual AACC conference in Atlanta, GA. SDIX will be at booth 3755 from July 26-28. SDIX’s Apo B can be customized to various automated immunoassay platforms. More specifically, factors such as detection limit, sensitivity, linearity and antigen excess (prozone) can be adjusted and controlled. “Reagent quality and lot-to-lot consistency are both major concerns for immunoassay companies. Selecting an SDIX customized reagent is an easy and efficient solution for these concerns,” commented Paul Dany K, SDIX’s IVD Product Manager. The Apo B product will be available to customers later this month in the form of both short and long-term contracting options. For additional information, please contact Paul Dany K at (302) 456-6789 or email@example.com. About SDIX( www.sdix.com) SDIX is a biotechnology company with a core expertise in creating better antigens, better antibodies and better assays for the pharmaceutical, biotechnology and food safety markets. For over 20 years, SDIX has been a leading immuno-solutions company, developing results-oriented and innovative antibody-based solutions that enable customers to meet high performance research, diagnostic and commercialization objectives. In the life science market, SDIX’s technology and capabilities are being used to help discover disease mechanisms, facilitate development of new drugs and provide antibodies and assays for the diagnosis of disease. In the food safety market, SDIX continues to expand its footprint as an international supplier of rapid pathogen test technologies that enable more accurate and cost-effective results. This news release may contain forward-looking statements reflecting SDIX's current expectations. When used in this press release, words like “anticipate”, “could”, “enable”, “estimate”, “intend”, “expect”, “believe”, “can”, “potential”, “will”, “should”, “project”, “plan” and similar expressions as they relate to SDIX are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDIX at this time. Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDIX's public filings with the U.S. Securities and Exchange Commission.
Shares of Strategic Diagnostics (Nasdaq:SDIX) have taken a tremendous swing upward. The stock is trading at $2.68 as of 12:22 p.m. ET, 20.7% above Thursday's closing price of $2.22. Volume is at 295,904, 8.7 times the daily average of 34,200.